浆膜腔灌注恩度联合顺铂用于恶性浆膜腔积液的临床观察  

Clinical Observation of Cavity Infusion Endostar Combined with Cisplatin in the Theatment of Malignant Cavity Effusion

作　　者：郭加友 方立俭[1] 郭嘉漪[1] 

机构地区：[1]江苏省连云港市东方医院,江苏连云港222042

出　　处：《中国医学创新》2016年第4期68-71,共4页Medical Innovation of China

摘　　要：目的:探讨血管内皮抑素(恩度)治疗恶性浆膜腔积液的近期疗效,并观察浆膜腔给药方式的安全性及患者的耐受性。方法:选取本院2012年1月-2015年1月收治的30例恶性中等量以上浆膜腔积液患者,均用浆膜腔穿刺尽可能抽出积液后给予腔内注射药物,13例患者为顺铂单药组,给予腔内灌注顺铂40 mg/次,d1,3,5;17例患者为顺铂联合恩度组,给予腔内灌注顺铂40 mg/次,d1,3,5+恩度30 mg/次,d1,3,5,1个周期后评价疗效及不良反应。结果:顺铂单药组完全缓解0例,部分缓解6例,疾病稳定6例,疾病进展1例,客观有效率46.2%;顺铂联合恩度组完全缓解1例,部分缓解12例,疾病稳定2例,疾病进展2例,客观有效率76.5%,两组客观有效率比较,差异无统计学意义(P=0.180)。27例疾病未进展患者中,顺铂单药组中位疾病进展时间为84 d,顺铂联合恩度组为100 d,两组比较差异有统计学意义(P=0.032)。两组不良反应相当,顺铂联合恩度组未增加不良反应,耐受性好。结论:恩度联合顺铂腔内灌注治疗恶性浆膜腔积液近期疗效较好,患者耐受性好。Objective： To observe the clinical short-term efficacy of cavity infusion of recombinant human endostatin （ endostar ） in the treatment of malignant cavity effusion, and evaluate the safety and tolerability of cavity infusion. Method： Thirty patients with more than medium malignant cavity effusion in our hospital from January 2012 to January 2015 were analyzed retrospectively. Following a maximum release all of cavity effusion, all the patients were given cavity infusion including 13 cases of cisplatin monotherapy group and 17 cases of endostar with cisplatin＇ group. The dosage was taken as follow： endostar 30 mg per time on dl, 3, 5; cisplatin 40 mg each time on dl, 3, 5. Their short-term efficacy as well as toxicity after a treatment cycle was evaluated. Results： In the cisplatin monotherapy group, there were 0 case achieved CR, 6 cases achieved PR, 6 cases achieved SD, 1 case achieved PD, the objective response rate was 46.1%, while in the endostar with cisplatin group, there were 1 case achieved CR, 12 cases achieved PR, 2 cases achieved SD, 2 cases achieved PD, the objective response rate was 76.4%. There were significant differences between the two groups （ P=0.180 ） . Among 27 responders median TIP of cisplatin monotherapy and endostar with cisplatin group were 84 days vs 100 days （ P=0.032 ） . Drug-related toxicity of two groups was similar. Conclusion： Cavity infusion endostar combined with cispaltin can control the malignant cavity effusion better, and its clinical safety is better than cisplatin monotherapy.

关 键 词：重组人血管内皮抑素 恶性浆膜腔积液 化学治疗 

分 类 号：R730.5[医药卫生—肿瘤]